OCC · ASX

Orthocell Ltd (ASX:OCC)

AU$1.24

 -0.01 (-0.8%)
ASX:Live
20/12/2024 04:10:10 PM
Volume Spike Recent Price upgrade Recent Earnings upgrade HALO Price Momentum HALO Ords +6
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

OCC Overview

OCC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Neutral

About OCC

Website

Orthocell Ltd

Telephone

61.8.9360.2888

Address

Building 191 90 South Street Murdoch University Murdoch, Western Australia (WA) 6150

Description

Orthocell Ltd. engages in the business of developing and commercializing biological medical devices and cell therapies. Its products include CelGro, which is a naturally derived collagen medical device for soft tissue repair; and Antilogous Tenocyte Implantation for chronic treatment resistant tendon injuries. The company was founded by Paul Frederick Anderson and Ming Hao Zheng on March 21, 2006 and is headquartered in Murdoch, Australia.

OCC Price Chart

Key Stats

Market Cap

AU$300.83M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.35 - 1.27

Trade Value (12mth)

AU$74,874.00

1 week

9.17%

1 month

100%

YTD

208.64%

1 year

204.88%

All time high

1.27

Key Fundamentals

EPS 3 yr Growth

-26.40%

EBITDA Margin

-210.00%

Operating Cashflow

-$7m

Free Cash Flow Return

-112.10%

ROIC

-123.80%

Interest Coverage

N/A

Quick Ratio

4.10

Other Data

Shares on Issue (Fully Dilluted)

209m

HALO Sector

Healthcare

Next Company Report Date

29-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

OCC Announcements

Latest Announcements

Date Announcements

19 December 24

US FDA Application Submitted for Remplir as US Launch Nears

×

US FDA Application Submitted for Remplir as US Launch Nears

12 December 24

Major Milestone with First Sales of Remplir in Singapore

×

Major Milestone with First Sales of Remplir in Singapore

10 December 24

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

03 December 24

Notification regarding unquoted securities - OCC

×

Notification regarding unquoted securities - OCC

03 December 24

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

03 December 24

Change of Director's Interest Notice-John Van Der Wielen

×

Change of Director's Interest Notice-John Van Der Wielen

03 December 24

Cleansing Notice

×

Cleansing Notice

02 December 24

Outstanding Remplir Study Results Pave Way for FDA Clearance

×

Outstanding Remplir Study Results Pave Way for FDA Clearance

02 December 24

Notification regarding unquoted securities - OCC

×

Notification regarding unquoted securities - OCC

02 December 24

Change of Director's Interest Notice-Paul Anderson

×

Change of Director's Interest Notice-Paul Anderson

29 November 24

AGM Addresses by Chair and Managing Director

×

AGM Addresses by Chair and Managing Director

29 November 24

Trading Halt

×

Trading Halt

29 November 24

Results of Annual General Meeting

×

Results of Annual General Meeting

27 November 24

Distributor Signed, Remplir Sales in Singapore to Commence

×

Distributor Signed, Remplir Sales in Singapore to Commence

11 November 24

Key Executives Appointed to Drive Remplir US Sales

×

Key Executives Appointed to Drive Remplir US Sales

07 November 24

Letter, Supp Notice of Meeting & Replacement Proxy Form

×

Letter, Supp Notice of Meeting & Replacement Proxy Form

31 October 24

Orthocell completes $17m Placement

×

Orthocell completes $17m Placement

31 October 24

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

31 October 24

Cleansing Notice

×

Cleansing Notice

29 October 24

Application for quotation of securities - OCC

×

Application for quotation of securities - OCC

29 October 24

Notification of cessation of securities - OCC

×

Notification of cessation of securities - OCC

29 October 24

Cleansing Notice

×

Cleansing Notice

25 October 24

$17m Placement to Drive Further Growth as US Approval Nears

×

$17m Placement to Drive Further Growth as US Approval Nears

25 October 24

Proposed issue of securities - OCC

×

Proposed issue of securities - OCC

25 October 24

Proposed issue of securities - OCC

×

Proposed issue of securities - OCC

OCC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.03 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.03 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.3 32.3 -12.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.02 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 0.07 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -89.7 61.8 -36.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -8.6 20.3 -10.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.05 0.03 0.02 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.04 0.03 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.1 -42.2 -34.5 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 195 197 202 Lock Lock Lock
Basic m Lock Lock Lock Lock 195 197 202 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 2 4 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 50.5 177.0 25.3 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 12 13 15 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 1 3 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 177.6 267.6 19.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock 54.4 72.1 68.8 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 46 28 31 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.5 12.7 -14.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -729.6 -229.9 -210.0 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -12 -10 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.2 10.5 -13.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -752.4 -243.0 -219.8 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -11 -9 -10 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -3 -3 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -6 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -0.8 31.4 -14.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -594.5 -147.3 -135.1 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -6 15 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 0 3 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -7 14 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.6 306.2 -153.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -4.4 3.3 -1.4 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 11 25 21 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 38 30 27 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -11 -24 -20 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 28 23 22 Lock Lock Lock
Equity $m Lock Lock Lock Lock 10 6 5 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 10 7 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -40.8 -36.5 -22.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -24.0 -21.1 -27.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -91.9 -101.6 -158.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -82.6 -120.4 -195.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -65.8 -74.3 -123.8 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -45.3 173.5 -112.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A -319.1 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.9 2.5 1.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -106.2 -394.5 -439.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.2 5.9 4.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.1 5.7 4.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 31.3 92.4 89.6 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -91.8 322.1 -122.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.1 0.3 5.2 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 1.3 1.4 1.5 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.2 0.3 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 214.3 20.6 25.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -734.5 -221.8 -192.5 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -29.7 -31.8 -38.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -24.0 -21.1 -27.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 3.8 4.8 5.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -91.9 -101.6 -158.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -91.9 -101.6 -158.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 282.5 254.3 243.2 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 2,837.0 1,049.1 70.4 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 3,119.6 1,303.4 313.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 902.8 473.4 225.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 2,216.8 830.0 87.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

OCC Shortsell

Frequently Asked Questions

The current share price of Orthocell Ltd (OCC:ASX) is AU$1.24.
The 52-week high share price for Orthocell Ltd (OCC:ASX) is AU$1.27.
The 52-week low share price for Orthocell Ltd (OCC:ASX)? is AU$0.35.
Orthocell Ltd (OCC:ASX) does not pay a dividend.
Orthocell Ltd (OCC:ASX) does not pay a dividend.
Orthocell Ltd (OCC:ASX) does not offer franking credits.
Orthocell Ltd (OCC:ASX) is classified in the Healthcare.
The current P/E ratio for Orthocell Ltd (OCC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.